{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-YHPPVYEG/a4abd9b3-06c1-452a-9d20-b07cf8872687/HTML","dcterms:extent":"32 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-YHPPVYEG/0fa95e29-c008-4f7e-847f-661fc0974087/PDF","dcterms:extent":"91 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-YHPPVYEG/21e458da-0cf5-405b-b85e-4205512df814/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-YHPPVYEG","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2001","dc:creator":["Brunčko, Aleksander","Kos, Mitja","Lampe-Ivanovska, Dalila","Primožič, Stanislav","Skerbinjek-Kavalar, Maja","Strbad, Ervin"],"dc:format":[{"@xml:lang":"sl","#text":"številka:12"},{"@xml:lang":"sl","#text":"letnik:70"},{"@xml:lang":"sl","#text":"str. 727-731"}],"dc:identifier":["ISSN:1318-0347","COBISSID:820799","URN:URN:NBN:SI:doc-YHPPVYEG"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Adolescenca"},{"@xml:lang":"en","#text":"Adolescence"},{"@xml:lang":"en","#text":"Asthma"},{"@xml:lang":"sl","#text":"Astma"},{"@xml:lang":"en","#text":"Body weight changes"},{"@xml:lang":"en","#text":"Child"},{"@xml:lang":"en","#text":"Growth"},{"@xml:lang":"en","#text":"Hydrocortisone"},{"@xml:lang":"en","#text":"Hydrocortizon"},{"@xml:lang":"sl","#text":"inhalacije"},{"@xml:lang":"sl","#text":"mladostniki"},{"@xml:lang":"en","#text":"Nebulizers and vaporizers"},{"@xml:lang":"sl","#text":"otroci"},{"@xml:lang":"sl","#text":"Otrok"},{"@xml:lang":"sl","#text":"Rast"},{"@xml:lang":"sl","#text":"Razpršilci in razprševalci"},{"@xml:lang":"sl","#text":"Respiratorno zdravljenje"},{"@xml:lang":"en","#text":"Respiratory therapy"},{"@xml:lang":"sl","#text":"Telesna teža, spremembe"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Spremljanje varnosti in učinkovitosti flutikazon propionata pri otrocih in mladostnikih z astmo| Follow-up of safety and effectiveness of fluticasone propionate in children and adolescents with asthma|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. For pediatric patients who suffer for persistent asthma, inhalation corticosteroid therapy is of an increasing importance. It has been known that inhalation therapy lowers drug related risks in this population. The present study aimed to show that protective therapy using inhalation corticosteroid fluticasone propionate (ICS-FP) improves the health status of children with asthma and that low doses of ICS-FP have no clinically significant side effects, even in a long term use. Methods. Sixty-five children with predominantly moderate asthma treated with protective anti-inflammatory drug ICS-FP for more that six months were monitored in an ambulatory setting. The study included children and adolescents aged 5-18 years. The efficacy of the protective treatment with ICS-FS was investigated by measurements of eosinophilic cationic protein (ECP) in serum and spirometric parameters at the beginning and after six months of the treatment. The safety of protective treatment was assessed with measurements of body mass and height of the children and morning serum cortisol levels. Results. During the protective treatment the number of asthma exacerbation diminished. The triggers of nonallergic exacerbations were physical activity, changes of weather and viral inflammations and the triggers of allergic asthma exacerbations were allergens (house-dust mite, pollens and animal dander) and infections. ECP values similary showed a statistically significant decrease from 43.1 +/- 27.8 nmol/L at the beginning to 20.3 +/- 13.0 nmol/L after six months. Values of spirometric parameters, expressed as percentage of normal values for the population under study, exhibited 7-14% improvement in the six months observation period. All their changes were statistically significant, e.g. in FEV1 from 82.8 +/- 12.4% to 96.3 +/- 16.0%. Despite regular and appropriate treatment with ICS-FP, no decrease in morning serum cortisol levels exceeding normal values were observed. From 417.1 +/- 138.4 nmol/L at the beginning of the study, cortisol levels fell to 357.1 +/- 12.3 nmol/L, a statistically significant difference. However, these changes were small relative to the normal range of cortisol diurnal variability. Measurements of body mass and height upon regular six months periods did not show significantly lower values from those in healthy populations of same ages. On the contrary, the observed sample even had a significantly higher body height (relative body height increase of 1.9%) and body mass (relative body mass increase of 7.3%) when compared to healthy population. Conclusions. Present study indicates that ICS-FP protective antiinflammatory treatment of children and adolescents is safe and effective related to the age of the patient and severity of exacerbations"},{"@xml:lang":"sl","#text":"Izhodišča. Pri otrocih s perzistentno astmo imajo pri zdravljenju inhalacijski kortikosteroidi (IKS) vse večji pomen. Znano je, da inhalacijsko dajanje zmanjšuje tveganje pri uporabi teh zdravil. Z raziskavo smo želeli dokazati, da zaščitno zdravljenje z inhalacijskim kortikosteroidom flutikazon propionatom (IKS-FP) izboljša zdravje otrok in da nizki odmerki IKS-FP, tudi če so jih bolniki prejemali dlje časa, nimajo klinično značilnih sistemskih neželenih škodljivih učinkov. Metode: Ambulantno smo spremljali 65 otrok s pretežno zmerno obliko astme, ki so prejemali zaščitno protivnetno zdravilo IKS-FP. Odmerek je bil odvisen od starosti bolnika in teže njegove bolezni. Zaščito so prejemali več kot šest mesecev. Študija je obravnavala otroke in mladostnike, stare med 5 - 18 let. Učinkovitost zaščitnega zdravljenja smo preverjali z meritvami serumskega ECP in spirometričnih parametrov na začetku in po šestih mesecih zaščite z IKS-FP ter z beleženjem pogostnosti in teže astmatičnih poslabšanj, varnost zaščitnega zdravljenja pa z meritvami jutranjih vrednosti kortizola v serumu ter meritvami telesne višine in teže otrok. Rezultati: Med zaščitnim zdravljenjem je bilo poslabšanj manj. Najpogostejši sprožilci poslabšanj nealergijske astme so bili telesni napor, spremembe vremena ter virusne okužbe, sprožilci poslabšanj alergijske astme pa alergeni (pršica, cvetni prah trav, živalska dlaka) ter okužbe. Vrednosti ECP so pokazale statistično značilen padec s 43,1 +/- 27,8 nmol/L na začetku študije na 20,3 +/- 13,0 nmol/L po 6 mesecih. Vrednosti spirometričnih preiskav, izražene v deležu normalnih vrednosti za dano populacijo, so pokazale izboljšanje za 7-14% v času opazovanja. Vse meritve so kazale statistično značilen porast, npr FEV1 od 82,8 +/- 12,4% na 96,3 +/- 16,0%. Pri rednem in pravilnem zdravljenju z IKS-FP smo ugotovili padec ravni jutranjega kortizola, kar se sklada s prejšnjimi raziskavami, vendar padec ne presega razpona normalnih vrednosti za starost. S 417,1 +/- 138,4 nmol/L na začetku študije je kortizol padel na 357,1 +/- 12,3 nmol/L. Kljub statistični značilnosti je bila sprememba v primerjavi z dnevnimi nihanji tega hormona sorazmerno majhna. Meritve telesne višine in teže pri otrocih ob šestmesečnih kontrolah niso pokazale vrednosti, ki bi bile značilno nižje pri zdravi populaciji. Nasprotno je imel obravnavani vzorec celo značilno večjo telesno višino (relativna telesna višina 1,9%) in telesno težo (relativna telesna teža7,3%) od populacijskih vrednosti v pripadajoči starosti. Zaključki: Ob zaključku študije ugotavljamo, da je IKS-FP učinkovito in varno protivnetno zaščitno zdravljenje astme pri otrocih in mladostnikih"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-YHPPVYEG","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-YHPPVYEG"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-YHPPVYEG/0fa95e29-c008-4f7e-847f-661fc0974087/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-YHPPVYEG/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-YHPPVYEG"}}}}